- Home
- KYMR vs GGAL Comparison
KYMR vs GGAL Comparison
Compare KYMR & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KYMR | GGAL |
|---|---|---|
| Founded | 2015 | 1905 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.6B |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | KYMR | GGAL |
|---|---|---|
| Price | $121.83 | $42.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 4 |
| Target Price | ★ $107.72 | $69.00 |
| AVG Volume (30 Days) | 613.0K | ★ 737.6K |
| Earning Date | 04-30-2026 | 03-07-2023 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,211,000.00 | N/A |
| Revenue This Year | $10.61 | $62.29 |
| Revenue Next Year | $8.17 | $22.88 |
| P/E Ratio | ★ N/A | $13.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.84 | $25.89 |
| 52 Week High | $130.05 | $62.11 |
Technical Indicators
Market Signals| Indicator | KYMR | GGAL |
|---|---|---|
| Relative Strength Index (RSI) | 67.81 | 31.78 |
| Support Level | $76.40 | $39.90 |
| Resistance Level | $130.05 | $45.01 |
| Average True Range (ATR) | 4.22 | 1.89 |
| MACD | 1.29 | -0.61 |
| Stochastic Oscillator | 91.57 | 0.92 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.